TGA Issues Advertising Guidance and Philippines Proposes Priority Processing for Local Pharma

Regulatory authorities in Australia and the Philippines are introducing new measures to tighten pharmaceutical advertising and incentivize domestic drug manufacturing. The Australian Therapeutic Goods Administration (TGA) has clarified its ban on prescription drug promotion, targeting trade names, chemical names, and indirect imagery in marketing materials. Meanwhile, the Philippine FDA is consulting on a fast-track registration process for locally produced medicines to reduce reliance on imports and support national health policy goals.

The Australian Therapeutic Goods Administration (TGA) has released new guidance detailing strict prohibitions on advertising prescription medicines to the general public. The agency clarified that companies must eliminate all references to prescription drugs in their materials, covering trade names like Botox and chemical names such as semaglutide, as well as abbreviations and colloquial terms like CBD or weight-loss injections. The TGA specifically noted that even indirect imagery, such as a blue pill logo resembling Pfizer’s Viagra, could constitute a violation. While exceptions exist for information provided directly to healthcare professionals or government-authorized activities, the TGA stressed that adding a disclaimer for consumers to consult a doctor does not make an otherwise prohibited advertisement compliant.

The Philippine Food and Drug Administration (FDA) is seeking to implement priority processing lanes for locally manufactured pharmaceuticals to bolster domestic self-sufficiency under the 2022–2030 medicine policy. Under the proposal, products that undergo substantive manufacturing steps in the Philippines—such as formulation, processing, or filling—would be eligible for expedited review times. The FDA plans to review initial license applications and major variations within 20 working days, while prescription drug registrations would receive decisions within 90 working days. This initiative aims to provide local manufacturers with a competitive edge and faster market entry, as current frameworks do not distinguish between the structural challenges of domestic production and imported goods.

In China, the National Medical Products Administration (NMPA) recently held talks with Novo Nordisk Chair Lars Rebien Sørensen to discuss regulatory oversight and the development of high-quality pharmaceuticals. This meeting comes as Novo Nordisk prepares to file for Chinese approval of its oral obesity treatment, Wegovy, trailing its competitor Eli Lilly, which filed for NMPA approval of its oral GLP-1 drug orforglipron late last year. Concurrently, the World Health Organization (WHO) has issued an alert regarding falsified versions of Novartis’ cancer drug Jakavi. These counterfeit medicines have been detected in Iran, Russia, and Türkiye, often sold through illicit online platforms and occasionally through legitimate pharmacy channels.